'Am heart j' presentation slideshows

VIRAL MYOCARDITIS

VIRAL MYOCARDITIS. DR JULIAN JOHNY THOTTIAN DM CARDIO RESIDENT CALICUT MEDICAL COLLEGE. INTRODUCTION. Inflammation of heart muscle Most common agents- viruses, parasites and autoimmune state

1.51k views • 83 slides

Stent and Adjunctive Therapy Selection in 2010

Stent and Adjunctive Therapy Selection in 2010 . Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy VP/Dean; Associate Dean for Clinical Affairs American University of Beirut Adjunct Professor of Medicine Emory University School of medicine. The different types of DES on the market.

639 views • 52 slides

Cesium: Cardiac Toxin and Radiological Threat

Cesium: Cardiac Toxin and Radiological Threat. Bob Hoffman New York City Poison Center, NY, USA. Overview. Chemistry Elemental Inorganic salts Radiological Toxicity Diagnosis Treatment. Elemental Cesium. Solid at 298K Liquid slightly above that Highly reactive with water.

644 views • 51 slides

Heart Failure Associate Professor Rob Doughty Dept of Medicine, The University of Auckland & Green Lane Cardiovascul

1.01k views • 49 slides

553 views • 41 slides

Diabetes en Revascularisatie

524 views • 35 slides

Dr. Altay ?ahin Hacettepe University Faculty of Medicine Department of Chest Diseases

Dr. Altay ?ahin Hacettepe University Faculty of Medicine Department of Chest Diseases. Chronic Thromboembolic Pulmonary Hypertension (CTEPH). CTEPH Definition About 50% of CTEPH have no documented history of VTE (Peacock A. Proc Am Thorac Soc 2006;3:608)

497 views • 30 slides

Volume Assessment

Volume Assessment. 2010. Old Paradigm. Na + = Volume H 2 O = Tonicity. ICF. ECF. Blood. TBW. Left sided failure DOE Orthopnea 90% sensitivity corr c pcwp PND. Right-sided Failure Abdominal pain Early satiety Nausea/vomiting Non-specific Fatigue Feeling cold Altered mentation.

299 views • 25 slides

Conflict of Interest in Human Subjects Research

Conflict of Interest in Human Subjects Research. Ross McKinney, Jr, MD Duke University Medical Center. Declarations. NIH Funding (CTSA, IMPAACT, PPRU) DSMBs for Gilead Sciences, Applied Genetic Technologies Corporation Unpaid consulting with GSK anticipated . Definition.

385 views • 23 slides

Disclosures

Outcomes of Temporary Interruption of Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation.

326 views • 20 slides

Validation of the Pooled Cohort 10-year Atherosclerotic Cardiovascular Disease Risk Equations

Validation of the Pooled Cohort 10-year Atherosclerotic Cardiovascular Disease Risk Equations. Paul Muntner, Lisandro D Colantonio, Mary Cushman, David C Goff Jr ., George Howard, Virginia J Howard, Brett Kissela , Emily B Levitan, Donald M. Lloyd-Jones, Monika M Safford

355 views • 17 slides

Table 1

Table 1. All figures quoted are for multivariate analyses of the predictive effect of transthoracic echocardiography.

166 views • 2 slides

Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI. 0.5. Component of composite endpoint Myocardial I nfarction. 0.4. No event. With event. 0.3. Proportion of patients stopping medication. 0.2. 0.1. 0. 360. 720. 1080. 1440. 1800. 2180. Days of follow up.

90 views • 2 slides